In this issue:
Treatment persistence with guselkumab vs IL-17A inhibitors
Long-term abatacept in individuals at risk of rheumatoid arthritis
Placebo and biologic treatment effect over time in axial spondyloarthritis
Biologic immunotherapy and risk of MACE
Effect of time to start of biologic therapy in childhood arthritis
Abatacept and rheumatoid arthritis-associated interstitial lung disease
TNF inhibitors and risk of depression in ankylosing spondylitis
Tocilizumab vs prednisone in established rheumatoid arthritis
Anifrolumab in systemic lupus erythematosus
Denosumab, teriparatide and romosozumab for glucocorticoid-induced osteoporosis
Please login below to download this issue (PDF)